TWI923576B - 高濃度抗Aβ原纖維抗體配製物及其使用方法 - Google Patents
高濃度抗Aβ原纖維抗體配製物及其使用方法Info
- Publication number
- TWI923576B TWI923576B TW110110263A TW110110263A TWI923576B TW I923576 B TWI923576 B TW I923576B TW 110110263 A TW110110263 A TW 110110263A TW 110110263 A TW110110263 A TW 110110263A TW I923576 B TWI923576 B TW I923576B
- Authority
- TW
- Taiwan
- Prior art keywords
- concentration
- arginine
- pharmaceutical formulation
- antibody
- histidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992746P | 2020-03-20 | 2020-03-20 | |
| US62/992,746 | 2020-03-20 | ||
| US202063027263P | 2020-05-19 | 2020-05-19 | |
| US63/027,263 | 2020-05-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202200201A TW202200201A (zh) | 2022-01-01 |
| TWI923576B true TWI923576B (zh) | 2026-05-01 |
Family
ID=75746958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110110263A TWI923576B (zh) | 2020-03-20 | 2021-03-22 | 高濃度抗Aβ原纖維抗體配製物及其使用方法 |
Country Status (28)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021310926A1 (en) | 2020-07-23 | 2023-03-23 | Othair Prothena Limited | Anti-abeta antibodies |
| JP2024525559A (ja) | 2021-07-09 | 2024-07-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病治療用バイオマーカー |
| KR20240142535A (ko) | 2022-02-02 | 2024-09-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | P-tau181 수준을 사용한 치료 방법 |
| CN120202218A (zh) | 2022-11-28 | 2025-06-24 | 卫材R&D管理有限公司 | 使用tau PET水平的治疗方法 |
| IL324807A (en) | 2023-06-09 | 2026-01-01 | Eisai R&D Man Co Ltd | Treatment methods using anti-Abeta protofibril antibody |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| MD3672631T3 (ro) | 2017-08-22 | 2023-09-30 | Biogen Ma Inc | Compoziții farmaceutice conținând anticorpi anti-beta amiloidici |
| WO2020023530A2 (en) * | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
-
2021
- 2021-03-19 PT PT217225382T patent/PT4121007T/pt unknown
- 2021-03-19 WO PCT/IB2021/000155 patent/WO2021186245A1/en not_active Ceased
- 2021-03-19 CA CA3174778A patent/CA3174778A1/en active Pending
- 2021-03-19 PL PL21722538.2T patent/PL4121007T3/pl unknown
- 2021-03-19 HR HRP20251087TT patent/HRP20251087T1/hr unknown
- 2021-03-19 US US17/906,660 patent/US20230183328A1/en active Pending
- 2021-03-19 DK DK21722538.2T patent/DK4121007T3/da active
- 2021-03-19 KR KR1020227030919A patent/KR20220156534A/ko active Pending
- 2021-03-19 FI FIEP21722538.2T patent/FI4121007T3/fi active
- 2021-03-19 MX MX2022011101A patent/MX2022011101A/es unknown
- 2021-03-19 CN CN202180019180.6A patent/CN115315251A/zh active Pending
- 2021-03-19 ES ES21722538T patent/ES3041762T3/es active Active
- 2021-03-19 MA MA59082A patent/MA59082B1/fr unknown
- 2021-03-19 SM SM20250350T patent/SMT202500350T1/it unknown
- 2021-03-19 JP JP2022556091A patent/JP7689141B2/ja active Active
- 2021-03-19 RS RS20250922A patent/RS67249B1/sr unknown
- 2021-03-19 BR BR112022018766A patent/BR112022018766A2/pt unknown
- 2021-03-19 PH PH1/2022/552172A patent/PH12022552172A1/en unknown
- 2021-03-19 MD MDE20230104T patent/MD4121007T2/ro unknown
- 2021-03-19 SI SI202130347T patent/SI4121007T1/sl unknown
- 2021-03-19 EP EP23179487.6A patent/EP4252777B1/en active Active
- 2021-03-19 LT LTEPPCT/IB2021/000155T patent/LT4121007T/lt unknown
- 2021-03-19 IL IL326613A patent/IL326613A/en unknown
- 2021-03-19 EP EP21722538.2A patent/EP4121007B1/en active Active
- 2021-03-19 AU AU2021238951A patent/AU2021238951A1/en active Pending
- 2021-03-19 HU HUE21722538A patent/HUE072937T2/hu unknown
- 2021-03-22 TW TW110110263A patent/TWI923576B/zh active
-
2022
- 2022-08-04 IL IL295383A patent/IL295383B2/en unknown
- 2022-09-12 CO CONC2022/0012916A patent/CO2022012916A2/es unknown
- 2022-09-14 CL CL2022002517A patent/CL2022002517A1/es unknown
-
2024
- 2024-11-08 CL CL2024003428A patent/CL2024003428A1/es unknown
-
2025
- 2025-04-10 JP JP2025064827A patent/JP2025111516A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2690850C2 (ru) | Составы на основе биспецифических антител к il-4/il-13 | |
| JP7689141B2 (ja) | 高濃度抗Aβプロトフィブリル抗体製剤及びその使用方法 | |
| RU2644214C2 (ru) | СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4 | |
| CA2885862A1 (en) | Stable, low viscosity antibody formulation | |
| JP2022166006A (ja) | 液体医薬組成物 | |
| TWI764097B (zh) | 包含抗cd47抗體的製劑及其製備方法和用途 | |
| KR20160068946A (ko) | 안정한 수성 항체 제제 | |
| EP3897714A1 (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
| US20250282882A1 (en) | Pharmaceutical formulation comprising anti-ox40 monoclonal antibody | |
| RU2846725C1 (ru) | ВЫСОКОКОНЦЕНТРИРОВАННЫЕ СОСТАВЫ НА ОСНОВЕ АНТИТЕЛ К ПРОТОФИБРИЛЛАМ Аβ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2745814C1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение | |
| KR20240100493A (ko) | 항-cd22 항체의 수성 제제 및 이의 용도 | |
| CN119997972A (zh) | 抗cd20抗体的药物组合物及其用途 | |
| HK40102754A (en) | High concentration anti-ass protofibril antibody formulations and methods of use thereof | |
| JP6820823B2 (ja) | 安定なIgG4に基づく結合剤の製剤 | |
| BR122025027938A2 (pt) | FORMULAÇÕES DE ANTICORPO DE PROTOFIBRILA ANTI-Abeta DE CONCENTRAÇÃO ALTA E MÉTODOS DE USO DAS MESMAS | |
| HK40085437B (en) | High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof | |
| HK40085437A (en) | High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof | |
| HK40059591A (en) | Preparations containing anti-cd47 antibody, and preparation method and use therefor | |
| HK1233918A (en) | Stable, low viscosity antibody formulation |